uniQure appoints Dan Soland as chief executive officer

Dutch human gene therapy specialist uniQure NV (Nasdaq: QURE) has named Dan Soland its chief executive officer. He will succeed Jörn Aldag, who will step down from the role he has held since 2009.

Mr Soland will also be nominated for appointment to uniQure's management board, subject to approval by the company's General Meeting of Shareholders.

Will Lewis, chairman of uniQure's Nomination and Governance Committee who led the search on behalf of the supervisory board, said: "Dan's appointment comes at an important time in the evolution and growth of uniQure. He brings significant operational experience and knowledge of drug development that will be critical as uniQure's pipeline advances into later-stage clinical studies.  I am confident that Dan's track record of generating shareholder value will enable uniQure to achieve the potential that we all believe is inherent in uniQure's broad pipeline and leading gene therapy technology platform."